Axcella Health Inc. (AXLA)
4.58
0.00 (0.00%)
At close: Jan 16, 2025, 9:00 PM
0.00
-100.00%
After-hours Dec 31, 1969, 07:00 PM EST
Company Description
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States.
The company treats complex diseases and enhances health using endogenous metabolic modulator compositions.
Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients.
The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016.
Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Axcella Health Inc.
| Country | United States |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Craig R. Jalbert CIRA |
Contact Details
Address: 840 Memorial Drive Cambridge, Massachusetts United States | |
| Website | https://www.axcellahealth.com |
Stock Details
| Ticker Symbol | AXLA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001633070 |
| CUSIP Number | 05454B105 |
| ISIN Number | US05454B2043 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Craig R. Jalbert CIRA | President, Chief Executive Officer, Treasurer, Secretary, Financial and Accounting Officer & Director |
| William R. Hinshaw Jr. | President, Chief Executive Officer & Director |
| Dr. Paul Fehlner J.D., Ph.D. | Senior Vice President, Chief Legal Officer & Corporate Secretary |
| Robert W. Crane | Senior Vice President & Chief Financial Officer |
| Virginia R. Dean | Senior Vice President & Chief People Officer |
| Dan Kirby | Senior Vice President of Strategic Operations |
| David R. Epstein B.Sc., M.B.A. | Consultant |
| Dr. Alison D. Schecter M.D. | President of Strategy & Operations |
| Dr. Karim Azer Ph.D. | Vice President of Platform & Discovery |
| Dr. Larry Bell | Global Head of Regulatory Affairs & Pharmacovigilance and Senior Vice President |
| Dr. Margaret James Koziel M.D. | Senior Vice President & Chief Medical Officer |
| Laurent Chardonnet | Consultant |
| Laurent Chardonnet M.B.A. | Consultant |
| Marie Washburn | Vice President of Finance & Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 15, 2024 | 25-NSE | Filing |
| Dec 22, 2023 | 8-K | Current Report |
| Dec 19, 2023 | 8-K | Current Report |
| Dec 04, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 8-K | Current Report |
| Nov 17, 2023 | S-8 POS | Filing |
| Nov 17, 2023 | S-8 POS | Filing |
| Nov 17, 2023 | DEF 14A | Filing |
| Nov 09, 2023 | 8-K | Current Report |
| Nov 06, 2023 | PRE 14A | Filing |